Search results for "vascular disorders"

showing 10 items of 79 documents

Antioxidant effects of resveratrol in cardiovascular, cerebral and metabolic diseases.

2013

Resveratrol-a natural polyphenolic compound-was first discovered in the 1940s. Although initially used for cancer therapy, it has shown beneficial effects against most cardiovascular and cerebrovascular diseases. A large part of these effects are related to its antioxidant properties. Here we review: (a) the sources, the metabolism, and the bioavailability of resveratrol; (b) the ability of resveratrol to modulate redox signalling and to interact with multiple molecular targets of diverse intracellular pathways; (c) its protective effects against oxidative damage in cardio-cerebro-vascular districts and metabolic disorders such as diabetes; and (d) the evidence for its efficacy and toxicity…

Antioxidantmedicine.medical_treatmentBiological AvailabilityPharmacologyResveratrolBiologyToxicologymedicine.disease_causeAntioxidantsNitric oxidechemistry.chemical_compoundMetabolic DiseasesDiabetes mellitusStilbenesOxidative stress antioxidant brain cardiovascular diabetes nitric oxideDiabetes MellitusmedicineHumansClinical Trials as Topicfood and beveragesGeneral Medicinemedicine.diseaseBioavailabilityCerebrovascular DisordersOxidative StresschemistryCardiovascular DiseasesResveratrolToxicityOxidation-ReductionOxidative stressIntracellularFood Science
researchProduct

The gut microbiota: An emerging risk factor for cardiovascular and cerebrovascular disease

2018

Commensal gut microbiota have recently been implicated in cardiovascular disease (CVD) and cerebrovascular disease. Atherosclerotic plaque formation depends on the colonization status of the host. In addition to host nutrition and the related microbiota-dependent metabolic changes, activation of innate immune pathways triggers the development of atherosclerosis and supports arterial thrombosis. Gnotobiotic mouse models have uncovered that activation of Toll-like receptor-2 by gut microbial ligands supports von Willebrand factor-integrin mediated platelet deposition to the site of vascular injury. Depending on nutritional factors, the microbiota-derived choline-metabolite trimethylamine N-ox…

Blood Platelets0301 basic medicineIntegrinsEmerging riskImmunologyDiseaseBiologyGut floradigestive systemMethylaminesMice03 medical and health sciencesVon willebrandRisk Factorsvon Willebrand FactormedicineAnimalsHumansImmunology and AllergyPlateletSymbiosisInnate immune systemInfant NewbornInfantThrombosisAtherosclerosisbiology.organism_classificationmedicine.diseaseThrombosisImmunity InnatePlaque AtheroscleroticToll-Like Receptor 2Gastrointestinal MicrobiomeCerebrovascular Disorders030104 developmental biologyCardiovascular DiseasesArterial thrombusImmunologyEuropean Journal of Immunology
researchProduct

Epigenomics in acute cerebrovascular diseases.

2020

Cancer ResearchMEDLINEBiologyDNA MethylationBioinformaticsBrain IschemiaEpigenesis GeneticCerebrovascular DisordersMicroRNAsDNA methylationGeneticsHumansEpigenesisEpigenomicsIschemic StrokeEpigenomics
researchProduct

Preclinical atherosclerosis and metabolic syndrome increase cardio- and cerebrovascular events rate: a 20-year follow up

2013

BACKGROUND: Intima-media thickness (IMT) is a validated marker of preclinical atherosclerosis and a predictor of cardiovascular events. PATIENTS: We studied a population of 529 asymptomatic patients (age 62 ± 12.8 years), divided into two groups of subjects with and without Metabolic Syndrome (MetS). METHODS: All patients, at baseline, have had a carotid ultrasound evaluation and classified in two subgroups: the first one without atherosclerotic lesions and the second one with preclinical atherosclerosis (increased IMT or asymptomatic carotid plaque). Cardiovascular endpoints were investigated in a 20-years follow-up. RESULTS: There were 242 cardiovascular events: 144 among patients with Me…

Carotid Artery DiseasesMaleAsymptomatic carotid plaqueIntima-media thicknessEndocrinology Diabetes and MetabolismMyocardial InfarctionMyocardial IschemiaMetabolic syndrome Preclinical atherosclerosis Intima-media thickness Asymptomatic carotid plaque Cardiac event Cerebrovascular eventsCarotid Intima-Media ThicknessBody Mass IndexAortic aneurysmRisk FactorsPreclinical atherosclerosisLongitudinal StudiesUltrasonography Doppler ColorOriginal InvestigationAged 80 and overMetabolic Syndromeeducation.field_of_studySmokingMiddle AgedPlaque AtheroscleroticStrokeIschemic Attack TransientHypertensionCardiologyFemalemedicine.symptomCardiology and Cardiovascular MedicineAdultmedicine.medical_specialtyCardiac eventPopulationEndarterectomyRisk AssessmentAsymptomaticAngina PectorisDiabetes mellitusInternal medicinemedicineHumansObesityeducationAgedDyslipidemiasAngiologyCerebrovascular eventsAortic Aneurysm Thoracicbusiness.industrymedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareCerebrovascular DisordersIntima-media thicknessAsymptomatic DiseasesMetabolic syndromebusinessBody mass index
researchProduct

High plasma levels of endothelin-1 enhance the predictive value of preclinical atherosclerosis for future cerebrovascular and cardiovascular events: …

2014

BACKGROUND AND PURPOSE: Clinical and experimental evidence suggests that endothelin-1 (Et-1) plays a role in cardiac and vascular disease. In the present study, we investigated the prognostic significance of Et-1 for cerebrovascular and cardiovascular outcome, in a 20-year follow-up. METHODS: We studied 82 originally healthy individuals, referred to our Unit of Cardiovascular Prevention, to evaluate the presence of asymptomatic carotid lesions. We subdivided these individuals into two groups, according to the plasma values of Et-1 (respectively ≤ or >2.7 pg/ml). Traditional cardiovascular risk factors were investigated, and by carotid ultrasound examination, we distinguished between normal …

Carotid Artery DiseasesMalePredictive Value of TestCarotid Intima-Media ThicknessRisk FactorsCardiovascular Diseasefollow-upProspective Studiescardiovascular events; cerebrovascular events; endothelin-1; follow-up; Adult; Aged; Asymptomatic Diseases; Biomarkers; Cardiovascular Diseases; Carotid Artery Diseases; Carotid Intima-Media Thickness; Cerebrovascular Disorders; Endothelin-1; Female; Follow-Up Studies; Humans; Male; Middle Aged; Plaque Atherosclerotic; Predictive Value of Tests; Prognosis; Prospective Studies; Risk Factors; Cardiology and Cardiovascular Medicine; Medicine (all)Prospective cohort studyEndothelin-1Medicine (all)Follow up studiesGeneral MedicineMiddle AgedPrognosiscardiovascular eventPredictive valuePlaque AtheroscleroticCardiovascular DiseasesPredictive value of testsCerebrovascular DisorderCardiologyFemaleCardiology and Cardiovascular MedicineHumanAdultmedicine.medical_specialtyPrognosicerebrovascular eventFollow-Up StudiePredictive Value of TestsCarotid Intima-Media ThickneInternal medicinemedicineHumansAsymptomatic DiseasesAgedAsymptomatic DiseaseCarotid Artery Diseasebusiness.industryVascular diseaseRisk FactorBiomarkermedicine.diseaseEndothelin 1Settore MED/11 - Malattie Dell'Apparato CardiovascolareProspective StudieCerebrovascular DisordersHigh plasmaAsymptomatic DiseasesbusinessBiomarkersFollow-Up Studies
researchProduct

Impact of preclinical carotid atherosclerosis on global cardiovascular risk stratification and events in a 10-year follow-up: comparison between the …

2019

Background The aim of the study was to compare three widely used algorithms for stratification of the global cardiovascular risk (GCVR): the Framingham Heart Study (FHS) score, the European systemic coronary risk estimation (SCORE) and the Italian 'Progetto Cuore' (heart project) score. It was also investigated how preclinical carotid atherosclerosis (pre-ATS) might influence the incidence and improve the risk prediction of cerebrovascular and cardiovascular events. Methods Subjects (n = 358) without previous history of cardiovascular disease (CVD) were recruited and the GCVR was calculated for each patient. An ultrasound evaluation of the carotid arteries was also performed. Results Accord…

Carotid Artery DiseasesMaleTime Factorsintima-media thickening (IMT)Predictive Value of TestDisease030204 cardiovascular system & hematologyCarotid Intima-Media ThicknessDecision Support Technique0302 clinical medicineFramingham Heart StudyRisk FactorsProspective Studies030212 general & internal medicineProspective cohort studyasymptomatic carotid plaque (ACP)education.field_of_studyIncidence (epidemiology)IncidenceGeneral MedicineMiddle AgedPrognosisPlaque AtheroscleroticAlgorithmItalypreclinical carotid atherosclerosis (pre-ATS)Predictive value of testsCerebrovascular DisorderDisease ProgressionFemalemedicine.symptomRisk assessmentCardiology and Cardiovascular MedicineAlgorithmAlgorithmsHumanAdultTime FactorPrognosiPopulationglobal cardiovascular risk (GCVR)AsymptomaticRisk AssessmentDecision Support TechniquesFollow-Up Studie03 medical and health sciencesPredictive Value of TestsCarotid Intima-Media ThicknemedicineHumanseducationAgedAsymptomatic DiseaseCarotid Artery Diseasebusiness.industryRisk Factoralgorithms of cardiovascular riskCerebrovascular DisordersProspective StudieAsymptomatic DiseasesbusinessFollow-Up Studies
researchProduct

Metabolic syndrome (MetS) predicts cardio and cerebrovascular events in a twenty years follow-up. A prospective study.

2012

BACKGROUND AND PURPOSE: Metabolic syndrome (MetS) is a cluster of cardiovascular risk factors, considered as emerging and promoting atherosclerosis. This study aimed at the evaluation of the influence of MetS on the prediction of cerebro and cardiovascular events during a 20 years follow-up period in an asymptomatic population of middle-aged subjects. METHODS: We evaluated 529 asymptomatic persons through a prospective study. Study population was divided into two subgroups: patients with and without MetS. Echo-color-Doppler was used in order to assess the presence of subclinical atherosclerosis. A 20 years follow-up study was carried out in order to estimate the incidence of cerebro and car…

Carotid Artery DiseasesMalemedicine.medical_specialtyTime FactorsPopulationMetabolic syndrome cardiovascular cerebrovascular eventsKaplan-Meier EstimateAsymptomaticCarotid Intima-Media ThicknessRisk AssessmentDisease-Free SurvivalAnginaRisk FactorsInternal medicinemedicineOdds RatioPrevalenceHumansProspective StudiesProspective cohort studyeducationStrokeAgedProportional Hazards ModelsMetabolic Syndromeeducation.field_of_studyChi-Square Distributionbusiness.industryIncidence (epidemiology)IncidenceOdds ratioMiddle Agedmedicine.diseaseAtherosclerosisPrognosisSettore MED/11 - Malattie Dell'Apparato CardiovascolareEchocardiography Doppler ColorCerebrovascular DisordersItalyAsymptomatic DiseasesMultivariate AnalysisCardiologyFemaleMetabolic syndromemedicine.symptomCardiology and Cardiovascular MedicinebusinessFollow-Up StudiesAtherosclerosis
researchProduct

Leukocyte Redistribution: Effects of Beta Blockers in Patients with Chronic Heart Failure

2009

BACKGROUND:Overproduction of pro-inflammatory cytokines is a well established factor in the progression of chronic heart failure (CHF). Changes in cellular immunity have not been widely studied, and the impact of standard medication is uncertain. Here we investigate whether a leukocyte redistribution occurs in CHF and whether this effect is influenced by beta-blocker therapy. METHODOLOGY:We prospectively studied 75 patients with systolic CHF (age: 68+/-11 years, left ventricular ejection fraction 32+/-11%, New York Heart Association class 2.5+/-0.7) and 20 age-matched healthy control subjects (age: 63+/-10 years). We measured the response of cells to endotoxin exposure in vitro, analysed su…

Cellular immunityAdrenergic beta-AntagonistsCardiovascular Disorders/Heart Failurelcsh:MedicineVentricular Function LeftAdrenergic beta-AntagonistsLeukocytesHumansMedicineIn patientProspective Studiescardiovascular diseaseslcsh:ScienceProspective cohort studyAgedHeart FailureMultidisciplinaryVentricular functionbusiness.industrylcsh:RCase-control studyMiddle AgedFlow Cytometrymedicine.diseaseCase-Control StudiesImmunology/Leukocyte ActivationHeart failureImmunologylcsh:QbusinessImmunology/Leukocyte DevelopmentResearch ArticlePLoS ONE
researchProduct

CNS manifestations of Fabry's disease

2006

Summary Background Fabry's disease is a rare hereditary lysosomal storage disease with multiorgan involvement. Deficiency of α-galactosidase A activity leads to accumulation of neutral glycosphingolipids, especially in vascular endothelial and smooth-muscle cells. Along with progressive renal and cardiac dysfunction, stroke is a major and often life-threatening burden of the disease. Cerebral vasculopathy, confirmed by neuropathological, neuroradiological, and functional studies, occurs commonly and leads to ischaemic cerebrovascular events at an early age. Recent developments Fabry's disease is an X-linked disease and women have been regarded as only mildly affected carriers. However, rese…

Central Nervous SystemPediatricsmedicine.medical_specialtyPathologybusiness.industryBrainEnzyme replacement therapyDiseaseTransient ischaemic attacksmedicine.diseaseFabry's diseaseFabry diseaseStrokeCerebrovascular DisordersmedicineLysosomal storage diseaseFabry DiseaseHumansNeurology (clinical)Young adultbusinessStrokeThe Lancet Neurology
researchProduct

Innovations in medical care and mortality trends from four circulatory diseases between 1970 and 2005

2013

Background: Governments have identified innovation in pharmaceuticals and medical technology as a priority for health policy. Although the contribution of medical care to health has been studied extensively in clinical settings, much less is known about its contribution to population health. We examine how innovations in the management of four circulatory disorders have influenced trends in cause-specific mortality at the population level. Methods: Based on literature reviews, we selected six medical innovations with proven effectiveness against hypertension, ischaemic heart disease, heart failure and cerebrovascular disease. We combined data on the timing of these innovations and cause-spe…

Estoniamedicine.medical_specialtyTime FactorsPopulation levelPsychological interventionMyocardial IschemiaPopulation healthMedical careSDG 3 - Good Health and Well-beingEnvironmental healthCause of DeathGermanySurveys and QuestionnairesMedicineHumansMortalityIntensive care medicineMortality trendsHealth policyNetherlandsHeart FailureSwedenbusiness.industryTherapies InvestigationalPublic Health Environmental and Occupational HealthHealth technologymedicine.diseaseUnited KingdomEuropeCerebrovascular DisordersSpainHeart failureHypertensionFrancebusinessEuropean Journal of Public Health
researchProduct